DNMT1 and Parkinson disease: DNMT inhibitors such as 5-aza-2’-deoxycytidine (5-aza-dC) can regulate the expression of neuroprotective genes, such as tyrosine hydroxylase, but also the transcription of PD-causing genes, such as UCHL1, through promoting hypomethylation.